On October 17, 2022, ICER released its draft evidence report, “Oral and Monoclonal Antibody Treatments for Relapsing Forms of Multiple Sclerosis.” This document provides a framework for considering what aspects of ICER’s review are important to people with multiple sclerosis (MS), and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.

Read the full report here.